Latest Breaking News On - Erin dunbar - Page 4 : vimarsana.com

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin Study to evaluate efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer Interim analysis of trial when 50% of planned subjects reach 6 months in study Sublicensee, WPD Pharmaceuticals to initiate a Phase 2 multicenter clinical trial in Poland of Berubicin in GBM in the second half of 2021; Interim analysis of the first 18 adult patients expected in first half of 2022 News provided by Share this article  (NASDAQ: CNSP) ( CNS or the Company ), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.

United statesErin dunbarJohn climacoUniversity of texas md anderson cancer centerReata pharmaceuticals incDrug administrationBrain tumor centerPharmaceuticals orphan drug designation for berubicinPharmaceuticals incPiedmont atlanta hospitalPrinciple investigatorOverall survivalOrphan drug designationReata pharmaceuticalsWaldemar priebeMedicinal chemistry